TFTeddy A. J. Fisher

Teddy A. J. Fisher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teddy A. J. Fisher has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Timothy E. Kennedy

    Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University

    2 shared publications
  • Cathleen Hudziak

    Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustrasse 3, Berlin 14195, Germany

    1 shared publication
  • Daniel Braatz

    Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustrasse 3, Berlin 14195, Germany

    1 shared publication
  • Daryan Chitsaz

    McGill Program in Neuroengineering, Integrated Program in Neuroscience, Department of Neurology and Neurosurgery Montreal Neurological Institute, McGill University, 3801 University Street, Montreal H3A 2B4, Canada

    1 shared publication
  • Ehsan Mohammadifar

    Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustrasse 3, Berlin 14195, Germany

    1 shared publication
  • Fatima El Ansari

    Department of Pharmacology and Therapeutics, McGill University

    1 shared publication

Latest Publications

  • Open Access

    Characterization of endothelin-converting enzyme 1 as a key enzyme in the multienzyme Aβ degradation pathway

    by Irem Ulku, Fatima El Ansari, Mark A. Hancock, Hedi Zhou, Gael Cagnone, Jean-Sebastien Joyal, Teddy A. J. Fisher, Timothy E. Kennedy, Filip Liebsch, Gerhard Multhaup

    Altered β-amyloid (Aβ) homeostasis is a critical event triggering the shift from healthy aging to Alzheimer disease (AD) through the overproduction and impaired clearance of Aβ peptides. The Aβ-degrading enzymes (ADEs) are a collective group of proteases that normally promote clearance to counteract Aβ-induced neurodegeneration. We previously discovered that the beta-site amyloid precursor protein cleaving enzyme 1 is an atypical ADE that produces the nontoxic fragment Aβ34 by recognizing 40- or 42-residue-long Aβ peptides as substrates in vitro and in vivo. Here, we examined other known ADEs for their potential roles in degrading Aβ34, Aβ40, and Aβ42. By genetic, cellular, and pharmacological approaches, we identified and characterized endothelin-converting enzyme 1 (ECE1) in a human neuroblastoma cell line, human brain vascular pericytes, and primary rat cortical cultures as a major enzyme degrading Aβ34 but not Aβ40 or Aβ42. Notably, we found that ECE1 cleaves Aβ34, an indicator of amyloid clearance, to a unique and unusually stable Aβ20-34 fragment that has the potential to serve as a measurable biomarker. Biocomputational analyses from non-AD controls and individuals with AD pathology showed that the highest messenger ribonucleic acid (mRNA) levels of ECE1 expression were found in pericytes (i.e., cells within the brain microvasculature that are known to produce Aβ34) compared to other cell types. Given Aβ34 is an indicator for prodromal AD, we postulate that our collective findings (i.e., generation of Aβ34 and Aβ20-34 intermediates within the “amyloidolytic” degradation pathway) will generate a set of biomarkers to detect amyloid clearance activity in vivo.


  • Molecular Biomimicry and the Synthetic Synapse: Engineering a Stable Synaptogenic Extracellular Matrix

    by Laila Al-Alwan, Jean-Pierre Clément, Teddy A. J. Fisher, Daniel Braatz, Daryan Chitsaz, Ehsan Mohammadifar, Cathleen Hudziak, Markus Hellmund, Janine Mauzeroll, Rainer Haag, et al.

    Synapses are highly specialized sites of asymmetric cell-cell contact that mediate information transfer between neurons. Many proteins have been identified that contribute to the complex processes that underlie the formation, organization, and maintenance of synapses, and the molecular biology of synapse formation is increasingly well understood. Surprisingly, synaptic differentiation does not require a cellular target. Hemisynaptic specializations form quickly at sites of neurite adhesion to microspheres coated with a synaptogenic protein or a synthetic cationic polypeptide like polylysine. This raises the possibility that functional hemisynaptic connections could be directed to form onto engineered surfaces; however, studies examining the stability of synaptic specializations formed in the brain onto polylysine-coated beads found that they were unstable and degraded within a few weeks after implantation. Here, we demonstrate that microbeads coated with dendritic polyglycerol amine (dPGA), a nonprotein macromolecular biomimetic of polylysine, promote enhanced synaptogenesis and synapse stability compared to conventional polylysine. We show that a dPGA coating is stable in long-term cell culture, resisting proteolysis, and that dPGA-coated beads cluster neurexin, which is sufficient to direct presynaptic terminal formation. We propose that synthetic synaptogenic extracellular matrices that resist proteolysis could be used to engineer electrodes with enhanced neural biocompatibility and support long-term bidirectional communication with neurons by directing the formation of stable synaptic specializations.


  • CA3 principal cell activation triggers hypersynchronous-onset seizures in a mouse model of mesial temporal lobe epilepsy

    by Siyan Wang, Maxime Lévesque, Teddy A. J. Fisher, Timothy E. Kennedy, Massimo Avoli

    Previous evidence suggested that different seizure onset patterns rely on the activity of distinct neuronal populations. In this study, we show for the first time that in vivo optogenetic stimulation of CaMKII principal cells in kainic acid-treated mice triggers hypersynchronous-onset seizures that are associated with fast ripples. Our findings indicate that in patients with predominant HYP-onset seizures, anticonvulsant treatments should be aimed at limiting the firing of principal neurons in the seizure onset zone.